Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Hiddo J Lambers HeerspinkPeter J GreasleyChristine AhlströmMagnus AlthageJamie P DwyerGordon LawEmma WijkmarkMin LinAnne-Kristina MercierMikael SunnåkerMichelle TurtonDavid C WheelerPhilip AmberyPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
This study evaluates the UACR lowering efficacy and safety of zibotentan with dapagliflozin as a potential new treatment for CKD. The study will provide information about an effective and safe zibotentan dose to be further investigated in a Phase 3 clinical outcome trial. Clinical Trial Registration Number: NCT04724837.